Acetyl cysteine

ApprovedSmall molecule

TTanta University

Acetyl cysteine is one of 103 small molecule programs targeting Psoriasis Vulgaris. It is currently in Approved.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriasis VulgarisActive, not recruiting

OtotoxicityActive, not recruiting

PneumoniaActive, not recruiting

VentilationRecruiting

Psoriasis VulgarisPhase 3

Active, not recruiting

OtotoxicityPhase 2

Active, not recruiting

PneumoniaApproved

Active, not recruiting

VentilationApproved

Recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Acetyl cysteine

TTanta University

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Jakafi

Incyte

Preclinical

1 4

Primaquine

Sanofi

Preclinical

1 5

Acanya

Pfizer

Preclinical

1 6

Prevacid

Takeda

Preclinical

1 7

Innohep

Alnylam Pharmaceuticals

Preclinical

1 8

Avlosulfon

AAlmirall, S.A.

Preclinical

4 9

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 10

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Ototoxicity

NCT07364747

Q2 2028

ApprovedRecruiting

Ventilation

NCT07409727

Clinical

Trials by Indication[1]

Post Operative Pain1 trial

Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine

Completed·RRadboud University Medical Center·Phase 4·NCT03354572·60 enrolled

Psoriasis Vulgaris1 trial

Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris

Unknown status·—·Phase 3·NCT05906498·60 enrolled

Pneumonia1 trial

Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella

Completed·TTanta University·Phase 1·NCT07097727·70 enrolled

NAC1 trial

Effect of High-Dose NAC on Patients With DPN

Unknown status·—·Phase 4·NCT04766450·30 enrolled

Ototoxicity1 trial

Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial

Recruiting·SSiriraj Hospital·Phase 2·NCT07364747·40 enrolled

2 more indications

AIN1 trial

N-Acetylcysteine Protection Against Radiation Induced Cellular Damage

Completed·CCentro Cardiologico Monzino·Phase 2·NCT04154982·181 enrolled

Ventilation1 trial

The Role of N-Acetylcysteine Inhalation in Critically Ill Mechanically Ventilated Patients

Recruiting·SSarah Rabie Mohamed Adly·Approved·NCT07409727·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Acetyl cysteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetyl cysteine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetyl cysteine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTanta University

Acetyl cysteine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Post Operative Pain1 trial

Psoriasis Vulgaris1 trial

Pneumonia1 trial

NAC1 trial

Ototoxicity1 trial

AIN1 trial

Ventilation1 trial

References

Drug Info

Quick Facts

Related News